Instructions for Credit —This activity is accredited for 1.25 continuing education credits for nurse practitioners, nurses, and social workers. Participants must attend the free webinar in its entirety, submit the online evaluation form and complete and submit the online post-test with a passing score of 70% to earn credit. Once submitted, the certificate will be automatically generated as a PDF online.
Please retain a copy of the certificate for your records. For questions regarding the accreditation of this activity, please contact Medical Learning Institute, Inc. at (609) 333-1693 or email@example.com.
You must be enrolled to complete this activity for credit, however, you are not required to enroll simply to view the presentation.
Target Audience — Nurse practitioners, nurses and oncology social workers involved in the care of patients with chronic lymphocytic leukemia (CLL).
Course Content Level for Social Workers — Intermediate and Advanced
Format: Non-interactive recorded webinar
|Learning Objectives — At the conclusion of this program, participants will be able to:|
|•||Describe the various types and subtypes of chronic lymphocytic leukemia (CLL)|
|•||Identify tests used to diagnose disease and monitor treatment of CLL|
|•||Explain the overarching goals of treatment for the types of CLL|
|•||Explain approved and emerging treatment options for CLL, including stem cell transplantation, and the role of clinical trials|
|•||Describe strategies to manage treatment side effects as well as potential long-term and late effects of treatments for CLL|
|•||Describe the roles of the pharmacist, the nurse and the social worker in treating patients with CLL|
Provider — This activity is provided by The Leukemia & Lymphoma Society.
Continuing Education for Nurse Practitioners, Nurses, and Social Workers
Registered Nursing Designation
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award continuing education contact hours through the California Board of Registered Nursing.
Social Worker Designation
The Leukemia & Lymphoma Society (LLS) Provider Number 1105, is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved as ACE providers. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. LLS maintains responsibility for this course. ACE provider approval period: 12/10/2020-12/10/2023. Social workers completing this course receive 1.25 continuing education credits.
The Leukemia & Lymphoma Society (LLS) is recognized by the New York State Education Departments State Board for Social Work as an approved provider of continuing education for licensed social workers #SW-0117. LLS maintains responsibility for the program. Social workers will receive 1.25 CE contact hours for this activity.
To view system requirements please go to https://llsce.org/system-requirements
For questions, grievances, or assistance with special needs (physical, etc.) please contact us at ProfEducation@LLS.org.
Disclosure of Conflicts of Interest — All faculty participating in continuing education activities by The Leukemia & Lymphoma Society are expected to disclose to activity participants any significant financial interest or other relationships with the manufacturer(s) of any commercial product(s) discussed in their presentations. The faculty are also expected to disclose any unlabeled or investigational uses of any product(s) discussed in their presentations.
William Wierda, MD, Research Support: AbbVie Inc., Acerta Pharma. Inc, Cyclacel Pharmaceuticals, Inc, Genentech, Gilead Sciences, Inc, GSK/Novartis, Janssen Pharmaceuticals Company of Johnson & Johnson, Juno Therapeutics, a Bristol Myers Squibb, Kite Pharma, a subsidiary of Gilead Sciences, Loxo Oncology, miRagen Therapeutics, Inc., Oncternal Therapeutics, Inc. Pharmacyclics, an AbbVie Company, Sunesis Pharmaceuticals, Inc, Xencor, Inc.
Deborah McCue, PharmD, BCOP, has nothing to disclose.
Jackie Broadway-Duren, DNP, APRN, FNP-BC, Advisory Board & Consultant: AbbVie.
Content/Peer Reviewer Disclosures
Ashley Ames, MSN, RN, FNP-BC, OCN, has nothing to disclose.
Disclaimer — Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
|Estimated time to complete activity: 1.25 hours|
|Date of initial release: May 15, 2020|
|Valid for CE credit through: October 31, 2021|
William Wierda, MD, PhD, is uniquely qualified to be the Principal Investigator (PI) for this grant owing clinical and translational research and expertise in CLL. In 2001, Dr. Wierda moved to Houston as an Assistant Professor of Medicine in the Department of Leukemia at MDACC. He was promoted to Associate Professor of Medicine in 2007. In 2012, he was promoted to Professor of Medicine and continue clinical and translational research in CLL. Dr. Wierda’s outpatient clinical activities are more than 90% dedicated to seeing and treating patients with CLL. At MDACC, Dr. Wierda has been PI, Co-PI, or collaborator on numerous clinical trials and conduct translational research in CLL. He has published many peer-reviewed articles on various clinical and translational aspects of CLL and drug development and have given numerous lectures on treatments for patients with CLL. Dr. Wierda’s particular research interests in CLL are prognostic factors and developing prognostic models in CLL, immune and gene therapies for patients with CLL, developing chemoimmunotherapy regimens and treatment strategies for relapsed and refractory patients with CLL.
Deborah McCue, PharmD, BCOP, is an Oncology Clinical Pharmacy Specialist at the University of Texas, MD Anderson Cancer Center in Houston. She is also a Manager of Clinical Pharmacy Services within the Division of Pharmacy. Dr. McCue received her Doctor of Pharmacy degree from the University of Maryland School of Pharmacy in Baltimore and completed her Pharmacy Practice Residency at the Veterans Affairs Medical Center in the Bronx, New York. She completed her Oncology Pharmacy Practice Residency at the MD Anderson Cancer Center. She has been a Board Certified Oncology Pharmacist since 1999. Her current area of practice and research is adult patients with hematologic malignancies.
Jackie B. Broadway-Duren, DNP, APRN, FNP-BC, is a Family Nurse Practitioner at the University of Texas, MD Anderson Cancer Center. Nurse Broadway-Duren’s expertise as a nursing professional, is vast and encompasses multiple specialty areas of practice including: oncology, immunology and primary health care. Her professional experience as it relates to chronic lymphocytic leukemia is extensive. Being an employee of MD Anderson Cancer Center since 2001, affords her the opportunity to work with world-renowned CLL experts. In addition, she participates in patient power educational programs, provides annual lectures on CLL to nurses and APRNs, serve as a facilitator in oncology education, is a consultant on advisory boards for pharmaceutical industries, and provides leadership to nurses and other members of interprofessional care teams. As an APRN, Nurse Broadway-Duren also serves as a Program Coordinator for the MD Anderson APRN Fellowship Program and presents bi-annual lectures on oncologic emergencies and other hematology related subjects.
Resources for HCPs
Online & In-person free CME & CE courses: www.LLS.org/CE
Treating Blood Cancers podcasts: www.LLS.org/HCPpodcast
Clinical Trials and Research
- Clinical Trials: Learn more about clinical trials: LLS.org/ClinicalTrials
- Research: Focused on finding cures, driving research in areas of unmet medical need, and bridging the gap between academic discovery & drug development: LLS.org/Research
Advocacy dedicated to removing barriers to care: www.LLS.org/Advocacy
Resources for Patients
CLL Specific Resources: www.LLS.org/CLL
Free Information Booklets: www.LLS.org/Booklets
Telephone/Web Education Programs: www.LLS.org/Programs
Support Resources : www.LLS.org/Support
- Financial Assistance
- Travel Assistance
- Referral to Medication Access programs
- Information Resource Center
- LLS Chapters
- LLS Community (social media platform)
- Patti Robinson Kaufman First Connection Program (peer-to-peer)
- One-On-One Nutrition Consultations (PearlPoint)
Information Resource Specialists: www.LLS.org/IRC
Assist through treatment, financial & social challenges, and give accurate treatment and support information. HCPs can also order free materials to distribute to patients.
Clinical Trial Support Center: www.LLS.org/CTSC
Patients & caregivers work one-on-one with an LLS Clinical Trial Nurse Navigator who will help find clinical trials and personally assist throughout the clinical trial process, providing an additional resource to the HCP team.
- Phone: (800) 955-4572, M-F, 9 am to 9 pm ET
- Email: infocenter@LLS.org
Live chat: www.LLS.org/InformationSpecialists
If you have any questions, please contact us at ProfEducation@LLS.org or call our Information Resource staff at 800-955-4572.